title: An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin.
abstract: Five patients with B-cell chronic lymphocytic leukemia (B-CLL) were treated with 6 courses of the anti-CD5 immunotoxin T101-ricin A chain (T101-RTA). Each course consisted of 8 bi-weekly infusions of T101-RTA (7 or 14 mg/m2). The immunotoxin was well tolerated in all cases with no major toxicities. Though saturation of circulating leukemic cell-associated target antigen was demonstrated by FACS analysis in all patients, no intact immunotoxin was detected in bone-marrow or lymph-node aspirates. Pharmacokinetic studies revealed rapid clearance of T101-RTA, with a half-life of 43 min. None of the patients developed detectable titers of antibody against either T101 murine antibody or ricin A chain. Clinical response was limited to a rapid and transient fall in WBC count lasting less than 24 hr, most likely secondary to the antibody portion of the conjugate. In vitro, fresh B-CLL cells were resistant to T101-RTA at concentrations up to 10(-8)M, while fresh malignant T-cells with a 10-fold increase in expression of CD5 antigen were sensitive. In the presence of the enhancing agent human serum albumin-monensin, fresh B-CLL cells were sensitive to T101-RTA, with an ID50 more than 2 logs below the maximal concentration of immunotoxin achieved in vivo. We conclude that T101-RTA is a potentially useful agent in the treatment of T-cell leukemias. In the presence of HSA-monensin, this spectrum of activity may be extended to B-CLL.
authors: Division of Hematology and Oncology, Duke University Medical Center, Durham, NC 27710.
authors: A A
authors: AA
authors: Hertler
authors: D M
authors: DM
authors: Schlossman
authors: M J
authors: MJ
authors: Borowitz
authors: H E
authors: HE
authors: Blythman
authors: P
authors: P
authors: Casellas
authors: A E
authors: AE
authors: Frankel
mesh_terms: D000368:Aged; D000906:Antibodies / Q000032:analysis / Q000627:therapeutic use; D000943:Antigens, Differentiation / Q000276:immunology*; D018956:CD5 Antigens; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000276:immunology / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012276:Ricin / Q000276:immunology*
chemical_list: D000906:Antibodies; D000943:Antigens, Differentiation; D018956:CD5 Antigens; D000922:Immunotoxins; D012276:Ricin